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influenza, reducing morbidity and mortality rates not only for those vaccinated,
but also for the entire population by reducing the spread of the virus. In the context
of contact network epidemiology, an individual who is located in the center of the
network is more likely to become infected. Thus, vaccinating such individuals
before others would be more efficient in reducing the influenza burden.METHODS:
We show that immunizing those who have been infected in the previous season,
especially before the peak of the disease, can substantially reduce infection rates
for a wide range of influenza viruses. Using the Susceptible Infected Recovered (SIR)
compartmental model we ran 2,100,000 simulations, each reflecting two successive
influenza seasons over a 1.5 million population contact network based on the
Portland population. The second season was checked for a Random Vaccination
Policy (RVP) and when using a vaccination policy prioritizing first those who were
infected in the previous season especially before the peak (PFIP). RESULTS: When
no vaccination is offered, individuals who became infected in the previous season
have a higher probability of becoming infected in the following season. Accord-
ingly, PFIP can reduce the number of infected by up to 80% compared to RVP, even
if the cross-reactivity rate between the viruses of two seasons is as high as 60-80%.
We provide a simple tool describing the conditions when each policy should be
used.CONCLUSIONS:No CDC recommendations have ever considered the effect of
a previous season on an individual in determining future vaccination policy. The
PFIP can be achieved easily by sending pamphlets, telephone reminders or even
family doctor recommendations to those who were diagnosed by the family doctor
as suffering from influenza like illness (ILI) in the previous season.
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OBJECTIVES: The UK Government has allocated £200 million per year for three
years to fund cancer drugs in England which will be managed via the Cancer Drugs
Fund (CDF). There are ten CDFs in England which are largely managed by Cancer
Network Pharmacists. The objective of this research was to identify from the Can-
cer Network Pharmacists’ perspective what impact the CDF had made in the first
year on cancer drug usage, practice, use of resources and also their concerns if the
CDF disappeared after three years. METHODS: A semi structured questionnaire
was developed to capture quantitative and qualitative data relating to changes in
oncology drug use, clinical practice and resources for the time period 1st April 2011
to 31st March 2012.This questionnaire was also used to capture information on the
Cancer Network Pharmacists concerns if the CDF disappeared after three years.
The questionnaire was piloted with three Cancer Network Pharmacists. Telephone
interviews were undertaken with Cancer Network Pharmacists covering the ten
CDFs. The data collected was assessed and evaluated, using a thematic framework.
RESULTS: The CDF had led to a significant increase in use of some drugs and
clinical practice had changed. Workload for pharmacy both at the cancer networks
and in the hospital Trusts had increased. Attendances at clinics had increased
creating some capacity issues. The commissioning process for cancer drugs had
changed; new drugs were not commissioned unless recommended by NICE. It was
considered there would be significant risks if the CDF disappeared after three years
as it was not clear how drugs funded by the CDF would then be funded and return
to practice pre CDF would be difficult. CONCLUSIONS: The CDF had changed clin-
ical practice for the management of certain cancers. If the CDF disappeared in 2014
it was unclear how some drugs would be funded.
PHS78
IMPACT OF EDUCATIONAL INTERVENTION ON CASE MANAGEMENT OF ARI AT
COMMUNITY PHARMACIES IN ISLAMABAD PAKISTAN
Hussain A1, Ibrahim MI2, Malik M3
1Hamdard university, Islamabad, Punjab, Pakistan, 2College of Pharmacy, Qatar University,
doha, Qatar, 3University Sains Malaysia, hamdard university, Islamabad, Pakistan
OBJECTIVES: To evaluate the impact of training of dispensers on the process of
case management of ARI at community pharmacies in context to history taking
and provision of advice working at community pharmacies in Islamabad, Pakistan.
METHODS: A randomized, controlled, blinded intervention study was designed
and implemented. Before the implementation of intervention, a baseline study was
performed to assess the process of case management for ARI at community phar-
macies. The study population included all community pharmacy outlets in Islam-
abad. After data collection, data was analyzed. The result of the study revealed that
the overall process of disease management of ARI at community pharmacies in
Pakistan is not satisfactory. Pharmacies of Islamabad which were visited in pre
intervention phase (118) were divided into two geographical regions A (interven-
tion) and B (control). From which thirty pharmacies were selected randomly from
each region. The targeted group of the interventions was drug sellers. Keeping in
view the results of the base line study an educational intervention was designed to
improve the case management of ARI at community pharmacies in Pakistan.
RESULTS: No significant difference (p  0.05) was seen in the process of history
taking and advice provision in case of ARI management at community pharmacies
between pre and post control groups. On the other hand significant difference in
the process of history taking and provision of advice for ARI was observed in the
intervention group before and after training. CONCLUSIONS: The study has high-
lighted that improvements in the current dispensing practices at community phar-
macies are possible through appropriate educational interventions. The dispens-
ers have the potential to provide fast and low cost health care to the masses in the
country where the presence of doctors and qualified pharmacist is low; to date they
are an untapped and underutilized source in the country.
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OBJECTIVES: To analyze the formation of formulary for specific drugs require-
ments at medical organizations(MOs) in Kazakhstan. METHODS: Questionnaires
were filled in by the members of the formulary committees (FC) at MOs (79 ones
from 4 regions of KZ) with different nosologies which had developed service; mor-
bidity recording; state drug provision system through single distributors (SD).
RESULTS: FCs mainly consisted of 34 % deputies of head doctors, 23 % pharmacists,
11 % nurses, 10 % head doctors, 8 % doctors, 1 % accountants; in only 1% of the MOs
clinical pharmacologists were amongst FCs. Moreover, 72 % had not trained in the
drug management; 12 % had experience a long time ago; 10 % improved qualifica-
tions in 2009-2010. The lists composed considering the profile and thus the specific
needs of the MOs (77 %); lists of drugs provided by the SD (58 %); the Republican
Formulary (44 %). 41 % of the MOs had access to the state register; just the third of
them had instructions with authorities for the members. Similar number of the
MOs had guidance/algorithms for filling in applications and accounts conductions.
The applications were filled in considering the extents of previous consumptions
(81 %); medical regimen (72 %); the patients’ number (70%); left amount of drugs
(63%); 94 % highlighted the toxicity to be considered for future lists. Amongst ad-
ditional factors, experience in specific drugs usage was pointed out (56 %); 18 %
claimed the insufficiency of information on tenders and vague choice criteria.
Noteworthy, 15 % stated the lobbying of some of drugs manufacturers.
CONCLUSIONS: Regardless to drugs provision by the state, there are obstacles in
the formation of FCs and formularies lists at the MOs: no presence of clinical
pharmacologists, no consideration of specific needs, poor training of the personnel.
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OBJECTIVES: To develop the clinical practice guideline major depressive disorder
for general practitioners in primary and secondary health care setting included the
diagnosis, differential diagnosis, severity classification and medical treatments.
METHODS:A list of 13 key elements of a CPG development process were developed
that consisted of: 1) setting the review teams; 2) determining the problems; 3)
determining health outcomes; 4) evidence based literature review; 5) meeting to
draft the CPG; 6) formulating draft of CPG; 7) apprising the content of CPG by
experts; 8) trail phase; 9) evaluating for trail phase; 10) developing the curricular for
CPG training; 11) preparing for CPG training; 12) evaluating; and 13) improving the
CPG related with evaluated results. RESULTS: There were 3 main processes in
clinical practice guideline major depressive disorder for general practitioners in
primary and secondary health care setting (CPG-MDD-GP) which were 1) Assess-
ment of major depressive disorder (clinical assessment using 9Q screening tool and
DSM-TR diagnostic criteria, differential diagnosis, diagnosis for major depressive
disorder and coding of diagnosis) 2) Management of major depressive disorder and
3) Management of hospitalized patients. General practitioners were satisfied with
the CPG-MDD-GP in trial phase. A total of 416 general practitioners in all provinces
were trained to use the CPG-MDD-GP then they would be followed and evaluated.
Psychiatrists in psychiatric hospitals/ institutes would be available for consultation
from the general practitioners. CONCLUSIONS: The CPG-MDD-GP should be dis-
tributed to all general practitioners in primary and secondary health care setting.
Next step, it would be useful for developing the CPG for MDD in the tertiary health
care setting.
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OBJECTIVES: Patients access to new drugs is particularly a challenging task in UK.
English Primary Care Trusts (PCT) play a key role in facilitating the new drug’s
entry. The PCTs differ from each others through their behaviors and characteris-
tics. The main purpose of this study is to bifurcate a total of 152 PCT in similar
clusters having homogenous behavior, applying several clustering approaches,
and to compare the different approaches METHODS: All available information
about the PCTS is obtained from public sources and one key data base. A total of
64 variables were identified and classified into 5 groups according to population’s
profile, prescription and patient’s characteristics, economic, financial as well as
organizational criteria. We applied three kinds of clustering approaches: the two
first, namely k-means (implemented both directly and indirectly) and Hierarchical
Agglomerative Clustering (HAC) are traditional ones while the third, namely Self
Organizing Map (SOM) is a variant of neural network architectures. Finally, contin-
gency analysis and khi-square statistics were considered to encircle both depen-
dencies and similarities between clusters RESULTS: Preliminary estimates have
identified five clusters (for each method) that are different in their intrinsic char-
acteristics. Contingency results reflect strong dependence between the direct k-
mean and both HAC and SOM: indeed clusters are not very widely scattered be-
tween them. The chi-square (p-value) test corroborates their homogeneity. The
indirect K-means reflects heterogeneity in cluster’s dispersions also confirmed by
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